Edesa Biotech Inc (EDSA) - Total Assets
Based on the latest financial reports, Edesa Biotech Inc (EDSA) holds total assets worth $12.38 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Edesa Biotech Inc (EDSA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Edesa Biotech Inc - Total Assets Trend (2008–2025)
This chart illustrates how Edesa Biotech Inc's total assets have evolved over time, based on quarterly financial data. See Edesa Biotech Inc (EDSA) shareholders funds for net asset value and shareholders' equity analysis.
Edesa Biotech Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Edesa Biotech Inc's total assets of $12.38 Million consist of 85.1% current assets and 14.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.8% |
| Accounts Receivable | $642.87K | 4.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.98 Million | 14.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Edesa Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EDSA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Edesa Biotech Inc's current assets represent 85.1% of total assets in 2025, an increase from 61.0% in 2008.
- Cash Position: Cash and equivalents constituted 79.8% of total assets in 2025, up from 54.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 14.6% of total assets.
Edesa Biotech Inc Competitors by Total Assets
Key competitors of Edesa Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Edesa Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.76 | 15.73 | 14.58 |
| Quick Ratio | 4.76 | 15.73 | 14.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.23 Million | $13.47 Million | $13.35 Million |
Edesa Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Edesa Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 39.36 |
| Latest Market Cap to Assets Ratio | 3.64 |
| Asset Growth Rate (YoY) | 254.8% |
| Total Assets | $13.53 Million |
| Market Capitalization | $49.23 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Edesa Biotech Inc's assets at a significant premium (3.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Edesa Biotech Inc's assets grew by 254.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Edesa Biotech Inc (2008–2025)
The table below shows the annual total assets of Edesa Biotech Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $13.53 Million | +254.76% |
| 2024-09-30 | $3.81 Million | -57.10% |
| 2023-09-30 | $8.89 Million | -23.20% |
| 2022-09-30 | $11.58 Million | -20.63% |
| 2021-09-30 | $14.58 Million | +35.52% |
| 2020-09-30 | $10.76 Million | +88.23% |
| 2019-09-30 | $5.72 Million | -51.46% |
| 2018-09-30 | $11.78 Million | +52.59% |
| 2017-09-30 | $7.72 Million | -40.33% |
| 2016-09-30 | $12.94 Million | +24.57% |
| 2015-09-30 | $10.39 Million | -28.24% |
| 2014-09-30 | $14.47 Million | +70.01% |
| 2013-09-30 | $8.51 Million | +451.43% |
| 2012-09-30 | $1.54 Million | -67.50% |
| 2011-09-30 | $4.75 Million | +64.21% |
| 2010-09-30 | $2.89 Million | +1093.15% |
| 2009-09-30 | $242.47K | +175.81% |
| 2008-09-30 | $87.91K | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more